Why Cybin Inc.’s (HELP) Stock Is Down 5.83%
As of Monday, August 31, Cybin Inc.’s HELP share price has dipped by 5.83%, which has investors questioning if this is right time to buy.Michael Rose
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Cybin Inc., doing business as Helus Pharma, a clinical stage pharmaceutical company, focuses on developing therapies to treat various psychiatric and neurological conditions.It develops HLP003, a deuterated psilocybin analog, which is in phase 3 clinical trial to treat major depressive disorder (MDD); and HLP004, a deuterated N, N-dimethyltryptamine (DMT), which is in phase 2 clinical trial for treating generalized anxiety disorders. The company’ preclinical product includes HLP005, a phenethylamine and tryptamine derivative to treat central nervous system. It has a strategic partnership agreement with Segal Trials to evaluating HLP003 for the adjunctive treatment of major depressive disorder; and with Osmind for mental health treatments. The company is headquartered in Toronto, Canada.
Commentary & Analysis
Why Cybin Inc.’s (HELP) Stock Is Down 7.39%
As of Monday, August 31, Cybin Inc.’s HELP share price has dipped by 7.39%, which has investors questioning if this is right time to buy.Rosalio Madrigal
Why Cybin Inc.’s (HELP) Stock Is Down 6.49%
As of Monday, August 31, Cybin Inc.’s HELP share price has dipped by 6.49%, which has investors questioning if this is right time to buy.Jenna Brashear
Why Cybin Inc.’s (HELP) Stock Is Down 5.36%
As of Friday, August 28, Cybin Inc.’s HELP share price has dipped by 5.36%, which has investors questioning if this is right time to buy.Jenna Brashear
Why Cybin Inc.’s (HELP) Stock Is Down 5.51%
As of Friday, August 28, Cybin Inc.’s HELP share price has dipped by 5.51%, which has investors questioning if this is right time to buy.Jenna Brashear
Financial Summary
| Share Statistics | HELP | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $892.8 | $674.5 | 43% |
|
| Shares Out (Mil) | 52.3 | 43.5 | 49% |
|
| Institutional Ownership | 73.8% | 84.6% | 45% |
|
| Float (Mil) | 59.3 | 47.3 | 51% |
|
| Beta | 0.56 | 0.71 | 32% |
|
| Avg Daily Volume (000s) | 1,533 | 290 | 80% |
|
| Price Change (52-week) |
104.4% | 69.3% | 92% |
|
| Growth | HELP | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 6.7% | na |
|
| Net Income (5yr) | (42.0%) | (1.4%) | 9% |
|
| EPS (5yr) | 15.3% | 15.0% | 57 |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | (40.2%) | (15.0%) | 11% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 5 | 4 | 2 | |
| Current EPS | ($0.683) | ($2.678) | ($1.836) | |
| Month Ago EPS | ($0.696) | ($2.949) | ($1.997) | |
| # Rev Up | 1 | 1 | 0 | |
| # Rev Down | 0 | 0 | 1 | |
| Three Months Ago EPS | ($0.784) | ($3.180) | ($2.867) | |
| Year/Year Chg | (25.3%) | (37.0%) | (78.2%) | |
| Financials | HELP | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $317 | na |
|
| Net Income (TTM) (Mil) | ($171) | ($11) | 7% |
|
| EPS (TTM) | ($4.049) | ($0.700) | 9% |
|
| Operating Cash Flow (TTM) (Mil) | ($141) | ($6) | 5% |
|
| Net Cash Flow (TTM) (Mil) | $48 | $5 | 69% |
|
| Long-Term Debt (Q1) (Mil) | $0 | $6 | 0% |
|
| Enterprise Value (Q1) (Mil) | $754 | $536 | 38% |
|
| Valuation | HELP | Industry Median |
Percentile (All Stocks) |
|
| P/B | 3.13 | 2.80 | 66% |
|
| P/E | na | 17.1 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.1 | na |
|
| Ratios | HELP | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 68.1% | na |
|
| Net Margin | na | (1.4%) | na |
|
| ROA | (72.8%) | (24.1%) | 8% |
|
| ROE | (86.9%) | (21.0%) | 10% |
|
| Liabilities to Assets | 6.8% | 32.3% | 4% |
|
| F-Score | 3 | 3 | 18% |
|
Passing Stock Screens
As of 9/4/2026, from a list of 60 stock screening strategies,
GURU STRATEGY
Lakonishok Screen
Factors: Value, Momentum
Identifying stocks trading at a discount to their industry norms but showing recent price strength and upward earnings revisions.
| Performance Since Inception: | 13.1% |
| +/- S&P 500: | +5.6 |
